Armata Pharmaceuticals Reports $115.3 Million Net Loss and Seeks Funding Amid Financial Challenges

Armata Pharmaceuticals, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $115.3 million for the three months ended March 31, 2026, compared to a loss of $6.5 million during the same period in 2025. The company's revenue from grants and awards increased to $789,000, up from $491,000 year-over-year, reflecting a 60.7% rise. However, total operating expenses also rose to $9.6 million, a 10.3% increase from $8.7 million in the previous year, primarily driven by higher research and development costs.

The substantial increase in net loss was largely attributed to a $101.1 million loss from the change in fair value of the company's Convertible Loan, which was a stark contrast to a gain of $5.2 million reported in the prior year. Interest expenses also surged to $5.6 million, up 54.3% from $3.6 million, due to increased debt balances. The company's accumulated deficit now stands at $616.9 million, raising concerns about its ability to continue as a going concern without additional funding.

In terms of strategic developments, Armata has been actively pursuing funding avenues to support its operations. On May 12, 2026, the company entered into a credit agreement for a secured term loan facility amounting to $25 million, which bears an interest rate of 14% and matures in January 2029. This loan is secured by the company's assets and is part of a broader strategy to extend the maturity dates of existing debt agreements with Innoviva Sub, which were also amended in January 2026.

Operationally, Armata continues to focus on its clinical pipeline, which includes two key product candidates: AP-PA02 and AP-SA02. The company has completed three Phase 2 clinical trials and is preparing for a Phase 3 study for AP-SA02, which targets complicated Staphylococcus aureus bacteremia. The FDA has provided guidance for this upcoming trial, which is expected to start in the second half of 2026. However, the company acknowledges that its current cash reserves of $4.8 million will not be sufficient to fund operations for the next 12 months, necessitating further capital raises through equity offerings, debt financing, or strategic partnerships.

Looking ahead, Armata's management remains focused on advancing its bacteriophage-based therapeutics while navigating the financial challenges posed by its current operating losses and the need for additional funding. The company is exploring various options to secure the necessary capital to continue its research and development efforts and to achieve regulatory approval for its product candidates.